HIV

Biktarvy（Low-Dose Tablet）is approved in the US for Treatment of HIV-1 in Children Weighing at Least 14 kg

FOSTER CITY, Calif October 18, 2021 Gilead Sciences, Inc. (Nasdaq: GILD) announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who…